# Study With [225Ac]Ac-FL-020 in mCRPC Participants

> **NCT06492122** · PHASE1 · RECRUITING · sponsor: **Full-Life Technologies GmbH** · enrollment: 50 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** [225Ac]Ac-FL-020
- **DRUG:** Blood samples for PK
- **DRUG:** [111In]In-FL-020
- **PROCEDURE:** Blood and urine samples collection
- **PROCEDURE:** SPECT/CT images

## Key facts

- **NCT ID:** NCT06492122
- **Lead sponsor:** Full-Life Technologies GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-30
- **Primary completion:** 2026-06
- **Final completion:** 2026-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06492122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06492122, "Study With [225Ac]Ac-FL-020 in mCRPC Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06492122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*